Nature Medicine, Published online: 04 June 2025; doi:10.1038/s41591-025-03734-3
A single-arm phase 2 trial in patients with mostly PD-L1-negative advanced triple-negative breast cancer shows that treatment with the anti-PD-L1 agent atezolizumab, paclitaxel and the anti-VEGF agent bevacizumab prolongs progression-free survival.
